Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial

Angela R. Branche, Nadine G. Rouphael, Cecilia Losada, Lindsey R. Baden, Evan J. Anderson, Anne F. Luetkemeyer, David J. Diemert, Patricia L. Winokur, Rachel M. Presti, Angelica C. Kottkamp, Ann R. Falsey, Sharon E. Frey, Richard Rupp, Martín Bäcker, Richard M. Novak, Emmanuel B. Walter, Lisa A. Jackson, Susan J. Little, Lilly C. Immergluck, Siham M. MahgoubJennifer A. Whitaker, Tara M. Babu, Paul A. Goepfert, Dahlene N. Fusco, Robert L. Atmar, Christine M. Posavad, Antonia Netzl, Derek J. Smith, Kalyani Telu, Jinjian Mu, Mat Makowski, Mamodikoe K. Makhene, Sonja Crandon, David C. Montefiori, Paul C. Roberts, John H. Beigel

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wild-Type spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.

Original languageEnglish
Pages (from-to)560-564
Number of pages5
JournalClinical Infectious Diseases
Volume77
Issue number4
DOIs
StatePublished - Aug 15 2023

Keywords

  • SARS-CoV-2
  • vaccine
  • variant

Fingerprint

Dive into the research topics of 'Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial'. Together they form a unique fingerprint.

Cite this